Sierra Oncology LLC - a GSK company

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Sierra Oncology LLC - a GSK company sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).

17 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Sierra Oncology LLC - a GSK company: 17 sponsored US clinical trials, none currently recruiting.

Sierra Oncology LLC - a GSK company sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 4 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Diffuse Large B-Cell, with 1 trials.

Top-decile sponsor footprint

Sierra Oncology LLC - a GSK company ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 1/100

11 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (64.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

17 total, page 1 of 1

COMPLETED Phase 3

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

NCT04173494
COMPLETED Phase 2

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

NCT02515630
TERMINATED Phase 2

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

NCT02378038
TERMINATED Phase 1

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

NCT02258607
COMPLETED Phase 2

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

NCT02226965
TERMINATED Phase 1

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

NCT02244489
TERMINATED Phase 1

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02206763
COMPLETED Phase 3

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
TERMINATED Phase 3

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

NCT02101021
COMPLETED Phase 2

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

NCT02124746
TERMINATED Phase 2

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

NCT01998828
COMPLETED Phase 3

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

NCT01969838
COMPLETED Phase 2

Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01733238
COMPLETED Phase 1

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

NCT01423058
COMPLETED Phase 2

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT01236638
COMPLETED Phase 1

A Study of PNT2258 in Patients With Advanced Solid Tumors

NCT01191775
COMPLETED Phase 1

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 7
Phase 3 4

Therapeutic Areas

Lymphoma, Diffuse Large B-Cell 1

How the Sierra Oncology LLC - a GSK company early-phase archive is shaped

17 indexed studies, none listed as recruiting (0% open); 11 completed (65%).

Phase mix: 4 late (III/IV) vs 13 early (I/II) (early-phase heavy).

Top condition: Lymphoma, Diffuse Large B-Cell (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Sierra Oncology LLC - a GSK company: archived-pipeline peers nationwide

Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Sierra Oncology LLC - a GSK company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%5%10%15%20%25% Total trials Recruiting share Sierra Oncology LLC - a GSK companyAchieve Life SciencesBioDelivery Sciences InternationalChugai PharmaceuticalConvaTec10xBio22nd Century Group23andMe3-C Institute for Social Development
Sierra Oncology LLC - a GSK company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sierra Oncology LLC - a GSK company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 17 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sierra Oncology LLC - a GSK company page

17 registered trials is a research-attention snapshot, not an endorsement of Sierra Oncology LLC - a GSK company or any single study.

  • None of Sierra Oncology LLC - a GSK company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Lymphoma, Diffuse Large B-Cell is the condition Sierra Oncology LLC - a GSK company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Diffuse Large B-Cell trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sierra Oncology LLC - a GSK company pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.